Traitement médical des tumeurs germinales testiculaires au stade métastatique

25 novembre 2008

Auteurs : M.O. Timsit, T. Lebret, P.-M. Lugagne, A. Méjean
Référence : Prog Urol, 2008, 18, S376, suppl. S7
   
 
 

 

 
Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser

   

 

 
 
 

Références

 

International germ cell consensus classification A prognostic factor-based staging system for metastatic germ cell cancers International Germ Cell Cancer Collaborative Group J Clin Oncol 1997 ;  15 : 594-603
 
Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., Loehrer P.J. Treatment of disseminated germ-cells tumours with cisplatin, bleomycin and either etoposide or vinblastine N Engl J Med 1987 ;  316 : 1435-1440 [cross-ref]
 
De Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J Clin Oncol 2001 ;  19 : 1629-1640 [cross-ref]
 
Culine S., Theodore C., Terrier-Lacombe M.J., Droz J.P. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis?. The need for a randomized trial J Urol 1997 ;  157 : 855-859 [cross-ref]
 
Toner G.C., Stockler M.R., Boyer M.J., et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial Australian and New Zealand Germ Cell Trial Group Lancet 2001 ;  357 : 739-745 [cross-ref]
 
Bajorin D.F., Sarosdy M.F., Pfister D.G., et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumours: a multiinstitutional study J Clin Oncol 1993 ;  11 : 598-606 [cross-ref]
 
Horwich A., Sleijfer D.T., Fossa S.D., et al. Randomized trial of bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial J Clin Oncol 1997 ;  15 : 1844-1852 [cross-ref]
 
De Wit R., Stoter G., Sleijfer D.T., et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group European Organization for Research and Treatment of Cancer Br J Cancer 1998 ;  78 : 828-832 [cross-ref]
 
Kaye S.B., Mead G.M., Fossa S., et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/ European Organization for Research and Treatment of Cancer study J Clin Oncol 1998 ;  16 : 692-771
 
Nichols C.R., Williams S.D., Loehrer P.J., et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol J Clin Oncol 1991 ;  9 : 1163-1172 [cross-ref]
 
Cushing B., Giller R., Cullen J.W., et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignantgerm cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children’s Cancer Group 8882 J Clin Oncol 2004 ;  22 : 2691-2700 [cross-ref]
 
Hinton S., Catalano P.J., Einhorn L.H., et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial Cancer 2003 ;  97 : 1869-1875 [cross-ref]
 
De Wit R., Stoter G., Sleijfer D.T., et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poorprognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group Br J Cancer 1995 ;  71 : 1311-1314 [cross-ref]
 
Culine S., Kramar A., Théodore C., et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/ cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP J Clin Oncol 2008 ;  26 : 421-427 [cross-ref]
 
Fossa S.D., Paluchowska B., Horwich A., et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor risk metastatic germ cell tumours (EORTC trial 30948) Br J Cancer 2005 ;  93 : 1209-1214 [cross-ref]
 
Droz J.P., Pico J.L., Biron P. No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor-risk non-seminomatous germ cell tumours: preliminary results of a randomized trial Proc Am Soc Clin Oncol 1992 ;  11 : 197
 
Hartmann J.T., Gauler T., Metzner B., et al. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group J Clin Oncol 2007 ;  25 : 5742-5747 [cross-ref]
 
Mencel P.J., Motzer R.J., Mazumdar M., Vlamis V., Barjorin D.F., Bosl G.J. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients J Clin Oncol 1994 ;  12 : 120-126 [cross-ref]
 
Bokemeyer C., Kollmannsberger C., Stenning S., et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin- based combination chemotherapy: a pooled analysis of two randomised trials Br J Cancer 2004 ;  91 : 683-687
 
Fizazi K., Tjulandin S., Salvioni R., et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group J Clin Oncol 2001 ;  19 (10) : 2647-2657 [cross-ref]
 
Flechon A., Bompas E., Biron P., Droz J.P. Management of postchemotherapy residual masses in advanced seminoma J Urol 2002 ;  168 (5) : 1975-1979 [cross-ref]
 
McCaffrey J.A., Mazumdar M., Bajorin D.F., Bosi G.J., Vlamis V., Motzer R.J. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival J Clin Oncol 1997 ;  15 : 2559-2563 [cross-ref]
 
Loehrer P.J., Gonin R., Nichols C.R., Weathers T., EInhorn L.H. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 1998 ;  16 : 2500-2504 [cross-ref]
 
Pico J.L., Rosti G., Kramar A., et al. A randomised trial of highdose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours Ann Oncol 2005 ;  16 : 1152-1159 [cross-ref]
 
Motzer R.J., Mazumdar M., Sheinfeld J., et al. Sequential doseintensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients J Clin Oncol 2000 ;  18 : 1173-1180 [cross-ref]
 
Kondagunta G.V., Bacik J., Sheinfeld J., et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors J Clin Oncol 2007 ;  25 : 85-90
 
Feldman D.R., Kondagunta G.V., Ginsberg M.S., et al. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors Invest New Drugs 2007 ;  25 : 487-490 [cross-ref]
 
Vuky J., Tickoo S.K., Sheinfeld J., et al. Salvage chemotherapy for patients with advanced pure seminoma J Clin Oncol 2002 ;  20 : 297-301 [cross-ref]
 
Gholam D., Fizazi K., Terrier-Lacombe M.J., Jan P., Culine S., Theodore C. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single- institution experience in 145 patients Cancer 2003 ;  98 : 745-752 [cross-ref]
 
Necchi A., Nicolai N., Piva L., et al. Long-term results of a combination of paclitaxel, oxaliplatin and gemcitabine as far rescue in heavily pre-treated male germ-cell tumors (GCT) J Clin Oncol 2008 ;  26 : 16036Abstract.
 
   
 
 
   

 

© 2008  Elsevier Masson SAS. Tous droits réservés.